Estrella Immunopharma, Inc. (ESLA)Healthcare | Biotechnology | EmeryVille, United States | NasdaqCM
1.88 USD
+0.22
(13.253%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.88 Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:05 p.m. EDT
ESLA is currently trading at $1.84, with a significant historical low of $0.78 over the past 52 weeks. The recent price movement shows a gradual increase, but the stock has been trading below its 50-day and 200-day moving averages, indicating weak momentum. The forward P/E ratio is negative, suggesting the company is not currently profitable, and the price-to-book ratio is also negative, which may indicate financial distress. The stock has no dividend history, and the short ratio is relatively high, indicating potential short-term selling pressure. Despite positive news such as a $8 million raise and a trial success, the overall fundamentals are weak, and the stock is not a strong candidate for either short-term or long-term investment. The forecasting model shows a very low predicted price increase, which further supports the cautious stance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.237368 |
| AutoARIMA | 0.237640 |
| AutoETS | 0.237665 |
| MSTL | 0.255501 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 80,210,632 |
| Forward P/E | -4.82 |
| Beta | 0.58 |
| Website | https://www.estrellabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2596154 |
| Address1 | 5,858 Horton Street |
| Address2 | Suite 370 |
| All Time High | 33.0 |
| All Time Low | 0.63 |
| Ask | 1.91 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 304,920 |
| Average Daily Volume3 Month | 205,227 |
| Average Volume | 205,227 |
| Average Volume10Days | 304,920 |
| Beta | 0.584 |
| Bid | 1.85 |
| Bid Size | 1 |
| Book Value | -0.273 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.88 |
| Current Ratio | 0.124 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.929 |
| Day Low | 1.56 |
| Display Name | Estrella Immunopharma |
| Ebitda Margins | 0.0 |
| Enterprise Value | 78,832,328 |
| Eps Current Year | -0.39 |
| Eps Forward | -0.39 |
| Eps Trailing Twelve Months | -0.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2805 |
| Fifty Day Average Change | 0.59949994 |
| Fifty Day Average Change Percent | 0.46817642 |
| Fifty Two Week Change Percent | 125.96154 |
| Fifty Two Week High | 3.15 |
| Fifty Two Week High Change | -1.2700001 |
| Fifty Two Week High Change Percent | -0.4031746 |
| Fifty Two Week Low | 0.78 |
| Fifty Two Week Low Change | 1.1 |
| Fifty Two Week Low Change Percent | 1.4102565 |
| Fifty Two Week Range | 0.78 - 3.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,631,626,200,000 |
| Float Shares | 18,021,366 |
| Forward Eps | -0.39 |
| Forward P E | -4.820513 |
| Free Cashflow | 3,429,978 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.6113 |
| Held Percent Institutions | 0.024600001 |
| Implied Shares Outstanding | 42,665,228 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc. |
| Long Name | Estrella Immunopharma, Inc. |
| Market | us_market |
| Market Cap | 80,210,632 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1802952199 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,063,512 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 80,637,280 |
| Number Of Analyst Opinions | 2 |
| Open | 1.66 |
| Operating Cashflow | -1,785,679 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 318 9098 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.88 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 1.66 |
| Price Eps Current Year | -4.820513 |
| Price Hint | 4 |
| Price To Book | -6.886447 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.102 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.22 |
| Regular Market Change Percent | 13.253 |
| Regular Market Day High | 1.929 |
| Regular Market Day Low | 1.56 |
| Regular Market Day Range | 1.56 - 1.929 |
| Regular Market Open | 1.66 |
| Regular Market Previous Close | 1.66 |
| Regular Market Price | 1.88 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 71,096 |
| Return On Assets | -2.5845199 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 42,665,228 |
| Shares Percent Shares Out | 0.0147 |
| Shares Short | 626,324 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 638,651 |
| Short Name | Estrella Immunopharma, Inc. |
| Short Percent Of Float | 0.0378 |
| Short Ratio | 11.79 |
| Source Interval | 15 |
| State | CA |
| Symbol | ESLA |
| Target High Price | 12.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 1,384,302 |
| Total Cash Per Share | 0.032 |
| Total Debt | 6,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.356745 |
| Two Hundred Day Average Change | 0.523255 |
| Two Hundred Day Average Change Percent | 0.38566938 |
| Type Disp | Equity |
| Volume | 71,096 |
| Website | https://www.estrellabio.com |
| Zip | 94,608 |